Drugs / DC371739
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04927221 | Apr → Dec 2021 | hyperlipidemia | Guangzhou JOYO Pharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04640012 | Sep 2020 → Mar 2021 | hyperlipidemia | Guangzhou JOYO Pharma Co., Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC371739 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927221 ↗ |
| Action | Inhibit | “impeding the transcription of both PCSK9 and ANGPTL3” PMID 35427476 ↗ Apr 2022 |
| Modality | Small molecule | “an indole-containing tetrahydroisoquinoline compound” PMID 35427476 ↗ Apr 2022 |
| Route | Oral | “single-dose oral administration” NCT04640012 ↗ |
| Target | ANGPTL3 | “impeding the transcription of both PCSK9 and ANGPTL3” PMID 35427476 ↗ Apr 2022 |
| Target | PCSK9 | “impeding the transcription of both PCSK9 and ANGPTL3” PMID 35427476 ↗ Apr 2022 |